Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02649582 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

Study acronym: ADDIT-GLIO
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 2024 to Jul 2027
    • Study completion date: Dec 2025 to Jul 2027
    v9
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  3. Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Dec 2024 to Dec 2025
    • Site contact updated
    • Study description shortened, about 1 word
    v7
  4. Primary completion date: Dec 2020 to Dec 2023
    • Study completion date: Dec 2022 to Dec 2024
    v6
  5. Eligibility criteria shortened, about 51 words
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study description expanded, about 9 words
    • Publications: 8 to 10
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Dec 2017 to Dec 2020
    • Study completion date: Dec 2019 to Dec 2022
    • Study description expanded, about 18 words
    • Publications: 7 to 8
    v4
  2. 2 versions Re-verified since Oct 28, 2016, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC) vaccination is added to adjuvant temozolomide maintenance treatment following (sub)total resection and temozolomide-based chemoradiation.
Trial Details
NCT Number NCT02649582
Lead Sponsor University Hospital, Antwerp
Conditions
(from sponsor)		 Glioblastoma Multiforme of Brain
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov